HIND (Vyome Holdings) Multiplikator nilai perusahaan marang pendapatan

The diversified biopharmaceutical logistics of Vyome Holdings Inc (HIND) maintains high profitability, as reflected by the EV/Sales dynamics on this GURU.Markets chart, where the value 31933.33 expresses the metric level. Stable sales of proprietary anti-inflammatory agents guarantee business reliability, while the current restructuring of R&D assets and the merger aim to expand sales channels for anti-obesity drugs to drive margin growth.
Rincian metrik keuangan lan pasar ReShape Lifesciences (HIND)

For Vyome Holdings Inc (HIND), which develops breakthrough immunodermatological drugs, the current EV/Sales ratio reflects the market's recognition of the brand's scientific potential. This metric compares the total enterprise value to annual revenue, excluding the impact of debt load, allowing investors to assess the asset's fundamental stability and the risk of overpaying for future clinical successes without distortions from the borrowing structure.